Department of Urology, Texas Tech University-Health Sciences Center, Lubbock, Texas, United States of America.
Department of Immunology and Molecular Microbiology, Texas Tech University-Health Sciences Center, Lubbock, Texas, United States of America.
PLoS One. 2020 Jun 2;15(6):e0234078. doi: 10.1371/journal.pone.0234078. eCollection 2020.
Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel's mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel's resistance mechanisms.
Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies.
While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial cross-resistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance.
Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies.
尽管有新的药物,转移性前列腺癌仍然是致命的。由于在疾病早期使用 cabazitaxel 紫杉烷类药物带来的生存获益、其有前途的新治疗组合和配方,以及其不同的毒性,最新批准的 cabazitaxel 紫杉烷类药物引起了极大的兴趣。然而,cabazitaxel 的耐药机制仍描述不足。因此,本研究的目的是建立一种新的 cabazitaxel 获得性耐药模型,以揭示 cabazitaxel 的耐药机制。
Du145 细胞用递增浓度的 cabazitaxel、多西紫杉醇/紫杉烷类对照药物或安慰剂/年龄匹配对照药物进行培养。一旦达到耐药性,通过细胞形态、细胞迁移和 E/M 标志物表达谱测试上皮-间充质转化(EMT)。通过 RNA 测序确定细胞转录组学;使用 IPA、PANTHER 或 KEGG 软件确定相关途径。通过 Western blot、药理学和敲低研究分析 Wnt 通路。
虽然年龄匹配的 Du145 细胞对两种紫杉烷类药物敏感,但多西紫杉醇耐药细胞仅对多西紫杉醇耐药,而 cabazitaxel 耐药细胞对两种药物表现出部分交叉耐药,同时发生 EMT。通过 RNA 测序,发现非典型 Wnt 通路仅在 cabazitaxel 耐药细胞中被激活,而典型 Wnt 通路仅在多西紫杉醇耐药细胞中被激活。cabazitaxel 耐药细胞在与多西紫杉醇耐药相关的 Wnt 通路相关基因上仅有微小的交叉,证实了我们对 cabazitaxel 获得性耐药的独特模型。药理学和 Western blot 研究证实了这些发现,并表明酪氨酸激酶受体 Ror2 受体在 cabazitaxel 耐药细胞中的作用。前列腺癌细胞中 Ror2 表达水平的变化改变了对两种药物的敏感性,这为紫杉烷类耐药的新靶点提供了可能。
本研究首次证明,尽管 Wnt 通路似乎在紫杉烷类耐药中发挥重要作用,但负责紫杉烷类药物特异性的 Wnt 效应器仍未确定,这促使我们需要进行更多的研究。